Press coverage about Sarepta Therapeutics (NASDAQ:SRPT) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.1588635165113 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Celgene Corporation (CELG), Sarepta Therapeutics Inc (SRPT): Analysts Share Two Cents on a Biotech Earnings Blunderer and a Champ (smarteranalyst.com)
- Edited Transcript of SRPT earnings conference call or presentation 25-Oct-17 8:30pm GMT (finance.yahoo.com)
- Sarepta: Beat and Raise…Again? (finance.yahoo.com)
- ‘They Are Seeing Benefits’: Sarepta CEO Discusses Success of Rare Disease Drug (finance.yahoo.com)
- Research Analysts Offer Predictions for Sarepta Therapeutics, Inc.’s Q3 2018 Earnings (SRPT) (americanbankingnews.com)
Several research analysts recently weighed in on SRPT shares. Janney Montgomery Scott lifted their price objective on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the stock a “fair value” rating in a research note on Monday, July 24th. Credit Suisse Group lifted their price objective on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an “outperform” rating in a research note on Thursday, September 7th. Nomura reissued a “buy” rating and set a $84.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. Needham & Company LLC reissued a “buy” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Finally, Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 16th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $64.10.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.31% during mid-day trading on Friday, hitting $47.79. 1,872,003 shares of the stock were exchanged. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $52.67. The stock’s 50 day moving average price is $48.16 and its 200-day moving average price is $38.57. The stock’s market capitalization is $3.07 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 62.44% and a negative net margin of 112.08%. The company had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same period last year, the business earned ($0.95) EPS. On average, equities research analysts expect that Sarepta Therapeutics will post ($1.03) EPS for the current fiscal year.
In other Sarepta Therapeutics news, SVP Shamim Ruff sold 11,500 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total transaction of $575,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 9.60% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Sarepta Therapeutics (SRPT) Share Price” was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/10/29/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-sarepta-therapeutics-srpt-share-price.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
What are top analysts saying about Sarepta Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sarepta Therapeutics Inc. and related companies.